78 related articles for article (PubMed ID: 27777971)
1. Evolving Antibody Therapies for the Treatment of Type 1 Diabetes.
Ke Q; Kroger CJ; Clark M; Tisch RM
Front Immunol; 2020; 11():624568. PubMed ID: 33679717
[TBL] [Abstract][Full Text] [Related]
2. The Role of T Cell Receptor Signaling in the Development of Type 1 Diabetes.
Clark M; Kroger CJ; Ke Q; Tisch RM
Front Immunol; 2020; 11():615371. PubMed ID: 33603744
[TBL] [Abstract][Full Text] [Related]
3. Anti-CD8 monoclonal antibody-mediated depletion alters the phenotype and behavior of surviving CD8+ T cells.
Cross EW; Blain TJ; Mathew D; Kedl RM
PLoS One; 2019; 14(2):e0211446. PubMed ID: 30735510
[TBL] [Abstract][Full Text] [Related]
4. Therapies to Suppress β Cell Autoimmunity in Type 1 Diabetes.
Kroger CJ; Clark M; Ke Q; Tisch RM
Front Immunol; 2018; 9():1891. PubMed ID: 30166987
[TBL] [Abstract][Full Text] [Related]
5. Type 1 Diabetes: A Chronic Anti-Self-Inflammatory Response.
Clark M; Kroger CJ; Tisch RM
Front Immunol; 2017; 8():1898. PubMed ID: 29312356
[TBL] [Abstract][Full Text] [Related]
6. TCR and Notch signaling in CD4 and CD8 T-cell development.
Laky K; Fleischacker C; Fowlkes BJ
Immunol Rev; 2006 Feb; 209():274-83. PubMed ID: 16448548
[TBL] [Abstract][Full Text] [Related]
7. Anti-coreceptor therapy drives selective T cell egress by suppressing inflammation-dependent chemotactic cues.
Martin AJ; Clark M; Gojanovich G; Manzoor F; Miller K; Kline DE; Morillon YM; Wang B; Tisch R
JCI Insight; 2016 Oct; 1(17):e87636. PubMed ID: 27777971
[TBL] [Abstract][Full Text] [Related]
8. Antibody Binding to CD4 Induces Rac GTPase Activation and Alters T Cell Migration.
Morillon YM; Lessey-Morillon EC; Clark M; Zhang R; Wang B; Burridge K; Tisch R
J Immunol; 2016 Nov; 197(9):3504-3511. PubMed ID: 27694496
[TBL] [Abstract][Full Text] [Related]
9. Coreceptor therapy has distinct short- and long-term tolerogenic effects intrinsic to autoreactive effector T cells.
Clark M; Kroger CJ; Ke Q; Zhang R; Statum K; Milner JJ; Martin A; Wang B; Tisch R
JCI Insight; 2021 Sep; 6(17):. PubMed ID: 34314385
[TBL] [Abstract][Full Text] [Related]
10. Regulation of TCR-induced IFN-gamma release from islet-reactive non-obese diabetic CD8(+) T cells by prostaglandin E(2) receptor signaling.
Ganapathy V; Gurlo T; Jarstadmarken HO; von Grafenstein H
Int Immunol; 2000 Jun; 12(6):851-60. PubMed ID: 10837413
[TBL] [Abstract][Full Text] [Related]
11. alpha/beta-T cell receptor (TCR)+CD4-CD8- (NKT) thymocytes prevent insulin-dependent diabetes mellitus in nonobese diabetic (NOD)/Lt mice by the influence of interleukin (IL)-4 and/or IL-10.
Hammond KJ; Poulton LD; Palmisano LJ; Silveira PA; Godfrey DI; Baxter AG
J Exp Med; 1998 Apr; 187(7):1047-56. PubMed ID: 9529321
[TBL] [Abstract][Full Text] [Related]
12. Both CD4+ and CD8+ T-cells in syngeneic islet grafts in NOD mice produce interferon-gamma during beta-cell destruction.
Suarez-Pinzon W; Rajotte RV; Mosmann TR; Rabinovitch A
Diabetes; 1996 Oct; 45(10):1350-7. PubMed ID: 8826970
[TBL] [Abstract][Full Text] [Related]
13. Anti-CD3/Anti-CXCL10 Antibody Combination Therapy Induces a Persistent Remission of Type 1 Diabetes in Two Mouse Models.
Lasch S; Müller P; Bayer M; Pfeilschifter JM; Luster AD; Hintermann E; Christen U
Diabetes; 2015 Dec; 64(12):4198-211. PubMed ID: 26293506
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
